Merus to Participate in the BIO Investor Forum
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
Chief Executive Officer, will be participating in the 2017 BIO Investor Forum in
a panel entitled, "Bispecific Antibodies to Supercharge Oncology Treatments" on
Tuesday, October 17, 2017 from 8:30-9:25 a.m. PT.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics®, which are based on the full-length IgG format, are manufactured
using industry standard processes and have been observed in preclinical studies
to have several of the same features of conventional monoclonal antibodies, such
as long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the
second half of 2017 in two metastatic breast cancer populations. MCLA-128 is
also being evaluated in a Phase 1/2 clinical trial in Europe in gastric,
ovarian, endometrial and non-small cell lung cancers. Merus' second bispecific
antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in
patients with acute myeloid leukemia. The Company also has a pipeline of
proprietary bispecific antibody candidates in preclinical development, including
MCLA-158, which is designed to bind to cancer stem cells and is being developed
as a potential treatment for colorectal cancer and other solid tumors, as well
as MCLA-145 designed to bind to PD-L1 and a non-disclosed second
immunomodulatory target, which is being developed in collaboration with Incyte
Corporation.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2017 - 22:08 Uhr
Sprache: Deutsch
News-ID 563172
Anzahl Zeichen: 2571
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus to Participate in the BIO Investor Forum"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
